Figure 2 | Scientific Reports

Figure 2

From: Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells

Figure 2

NVP-BEZ235 modulates AURKA expression in cells deficient for VHL. (A, C) VHL-proficient and VHL-deficient cells were treated with Vehicle or NVP-BEZ235 (Bez) as indicated and blotted for the antibodies shown. (B) Densitometric analysis graphed to show the ratio of phospho-AKT to total AKT. Black bars—siC (scrambled control) and gray bars—siVHL. #Statistical significance (Students t-test) compared to vehicle (DMSO) treated control (siC) (p < 0.001), **statistical significance (Students t-test) compared to vehicle treated siVHL (p-values as indicated). (D) Graphical representation of densitometric data showing fold-change in AURKA mRNA expression. Black bars—siC and gray bars—siVHL. #Statistical significance (Students t-test) compared to vehicle (DMSO) treated control (siC) (p < 0.001), **statistical significance (Students t-test) compared to vehicle treated siVHL (p-values as indicated). (E) Graphical representation of densitometric data showing fold-change in VHL mRNA expression. Black bars—siC and gray bars—siVHL. #Statistical significance (Students t-test) compared to siC for each of the treatment conditions (p < 0.05). (F) Three VHL-null RCC cells lines (786-0, 769-P, A-498) treated with Vehicle and NVP-BEZ235 (Bez) at the indicated doses and blotted as shown.

Back to article page